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PAcute Myocardial Infarction
Longer-Term Follow-Up of Patients Recruited to the
REACT (Rescue Angioplasty Versus Conservative
Treatment or Repeat Thrombolysis) Trial
Amanda Carver, MSC, BA (HONS), RN,* Suzanne Rafelt, BSC (HONS), MSC,†
Anthony H. Gershlick, BSC, MB, BS,‡ Kathryn L. Fairbrother, BA, RN,§
Sarah Hughes, BA (HONS), RN,§ Robert Wilcox, BSC, DM, for the REACT Investigators
Brisbane, Queensland, Australia; and Leicester and Nottingham, United Kingdom
Objectives To evaluate the longer-term outcomes for rescue percutaneous coronary intervention (R-PCI).
Background Thrombolysis remains an important, commonly used reperfusion therapy, yet failure to achieve complete reper-
fusion occurs relatively frequently. A number of recent trials have focused on the management of patients with
thrombolytic failure, including the REACT (Rescue Angioplasty Versus Conservative Treatment or Repeat Throm-
bolysis) trial, which demonstrated a significant 6-month benefit favoring R-PCI. However, longer-term mainte-
nance of benefit for R-PCI has not been demonstrated.
Methods Rates of the primary composite end point (major adverse cardiac and cerebrovascular events) to 1 year and
mortality to a median of 4.4 years in 427 patients included in the 3 randomized arms of the REACT trial (repeat
lysis, conservative therapy, and R-PCI) were analyzed.
Results One-year event-free survival for patients randomized to R-PCI was 81.5%, compared with 64.1% for repeat
thrombolysis and 67.5% for conservative therapy (overall p  0.004). Adjusted hazard ratio was 0.44 (95% con-
fidence interval [CI]: 0.28 to 0.71; p  0.0008) for R-PCI versus repeat thrombolysis and 0.51 (95% CI: 0.32 to
0.83; p  0.007) for R-PCI versus conservative therapy. Adjusted hazard ratio for longer-term (median 4.4 years)
overall mortality for R-PCI versus repeat thrombolysis was 0.41 (95% CI: 0.22 to 0.75; p  0.004) and 0.43
(95% CI: 0.23 to 0.79; p  0.006) for R-PCI versus conservative therapy. There was no difference in either analy-
sis between repeat thrombolysis and conservative strategies.
Conclusions Rescue PCI, previously shown to be superior in the short term to both repeat thrombolysis and conservative ther-
apy, maintains benefit in terms of long-term mortality. This strategy for failed lysis should be mandated as part
of thrombolytic-based ST-segment elevation myocardial infarction protocols. (J Am Coll Cardiol 2009;54:
118–26) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.03.050c
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ffter acute coronary artery occlusion, the short-, medium-,
nd longer-term outcomes are improved if a patent infarct-
elated vessel (1,2) and better Thrombolysis In Myocardial
nfarction (TIMI) flow grade can be achieved (3). Primary
ercutaneous coronary intervention (P-PCI) has increas-
ngly become the preferred option for patients presenting
ith ST-segment elevation myocardial infarction (STEMI),
ecause higher rates of TIMI flow grade 3 are achieved
rom the *Queensland Health, Brisbane, Queensland, Australia; †Department of
ardiovascular Sciences, University of Leicester, Leicester, United Kingdom; ‡De-
artment of Academic Cardiology and §Cardio-Respiratory Directorate, University
ospitals of Leicester NHS Trust, Leicester, United Kingdom; and the University
ospital, Nottingham, United Kingdom. The REACT trial was funded via a
rogram grant awarded by The British Heart Foundation. Repeat thrombolytic was
rovided by Roche Pharmaceuticals.r
Manuscript received September 10, 2008; revised manuscript received March 23,
009, accepted March 24, 2009.ompared with thrombolysis (4,5). Although its apparent
isadvantage compared with P-PCI has resulted in a reduc-
ion in the use of thrombolysis, it remains an important
rst-line treatment for at least one-third of those presenting
ith STEMI (6–8) due to geography, demographics, dif-
culties in initiating a P-PCI service and delivering P-PCI
ithin recommended timelines, and lack of facilities and
rained personnel at hospitals where many patients present,
s well as difficulties in changing established practice.
See page 127
Thrombolysis fails to achieve TIMI flow grade 3 in
pproximately 40% of patients (9,10), constituting “lytic
ailure” and recognized clinically as failure of ST-segment
esolution. Until recently it was unclear how best to manage
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July 7, 2009:118–26 The REACT Trial: Longer-Term Follow-Upuch patients. Given the advantages of P-PCI, it seemed
ntuitive to undertake so-called rescue percutaneous coro-
ary intervention (R-PCI) to mechanically open the artery.
owever, patients who experience lytic failure are inher-
ntly different from those undergoing P-PCI, presenting
ater to percutaneous coronary intervention (PCI), poten-
ially being clinically unstable due to prolonged occlusion
imes, and requiring PCI to be undertaken in the presence
f systemic thrombolytic. Most importantly, although evi-
ence exists supporting the advantages of P-PCI over lysis,
ntil recently there was little evidence to support the use of
-PCI as an adjunct to thrombolysis, with no data to
ndicate longer-term benefits until now.
The REACT (Rescue Angioplasty Versus Conservative
reatment or Repeat Thrombolysis) trial randomized pa-
ients with failed thrombolysis to 1 of 3 groups: repeat
hrombolysis, conservative therapy, or R-PCI. Primary end
oint outcomes to 6 months published in 2006 demon-
trated a significant benefit for the R-PCI group (11).
ong-term outcome in patients who have experienced lytic
ailure has been previously reported in only 1 other trial,
ERLIN (Middlesbrough Early Revascularization to
imit Infarction) (12), which showed different early out-
omes from those of the REACT trial. Furthermore,
ecause events occurred in all 3 REACT treatment groups
hroughout the initial 6-month follow-up, any differences in
utcome may have become attenuated over time. This study
herefore reports the 1-year major adverse cardiac and
erebrovascular events (MACCE) and late (up to 5 years)
ortality for the REACT trial patients.
ethods
etween December 1999 and March 2004, 427 patients
ere recruited from 35 sites across the United Kingdom, of
hich 19 had interventional facilities. Adults (age 21 to 85
ears) presenting with acute STEMI within 6 h of onset of
hest pain for whom any thrombolytic treatment had failed
o achieve reperfusion (defined as 50% resolution of the
aximal ST segment on 90-min electrocardiogram [ECG])
ere considered for inclusion in the study. After written
onsent was obtained, patients were randomly assigned via a
4-h computer-generated random-allocation system to 1 of
groups: repeat (fibrin-specific) thrombolysis, conservative
anagement (heparin for 24 h and routine care), or R-PCI,
elivered as soon as feasible, with transfer if needed to an
nterventional center. Patients were excluded if the pre-
icted ability to perform R-PCI was likely to be more than
2 h from symptom onset. Remaining exclusions were
riven by safety, particularly considering bleeding risk for
he repeat thrombolysis group. Baseline characteristics are
hown in Table 1. Power calculations dictated 156 patients
er group to demonstrate a 40% relative reduction in the
rimary end point (composite of death, recurrent acute
yocardial infarction [re-AMI], severe [New York Heart
ssociation functional class III or IV] heart failure, and eerebrovascular accident [CVA]),
ith 80% power at 6 months.
ompetition from other studies
ed to declining recruitment and,
long with a finite funding pe-
iod, necessitated termination of
he trial with 427 patients re-
ruited (repeat thrombolysis, n
42; conservative treatment, n 
41; R-PCI, n  144). Of the
atients randomized to R-PCI,
6 crossed to alternative arms, 13
ad patent arteries at angiogra-
hy, and 115 proceeded to an-
ioplasty, which was deemed
uccessful in all but 9 cases. Me-
ian time from randomization to
epeat thrombolysis administra-
ion was 190 min and to R-PCI
as 274 min. The times from
hest pain to initiation of these
espective randomized strategies
ere 330 min (5.5 h) and 414
in (6.9 h). The composite end
oint outcomes at 6 months were
ublished in 2006 (11).
onger-term data collection.
atients were followed up to 1
ear through clinic visit or tele-
hone contact. All data were
ource-verified according to strictly controlled criteria. The
ncidence of the components of the primary composite
utcome (death, re-AMI, severe heart failure, or confirmed
VA) was collected and event-free survival determined.
ates of ischemia-driven revascularization were collected as
econdary end points. All events were adjudicated by a
linded independent end point committee. Although
ollow-up to 1 year was part of the original protocol, the
bserved trend in mortality difference at 6 months led us to
onsider long-term death rates as a point of further interest,
nd ethical committee approval was granted to determine
ate mortality. Mortality status (including mode of death
cardiac or noncardiac] and median time to death after
andomization) was determined at each individual partici-
ating center through the National Health Tracing Service,
hich provides reliable, freely available mortality data from
he United Kingdom Government Office of National Sta-
istics via the patient-specific National Health Service iden-
ification number.
tatistical analyses. Analyses were performed on both an
ntention-to-treat basis and according to actual (initial)
reatment received (18 patients did not receive their ran-
omly assigned therapy). All 427 patients were included in
he analyses, as censored observations at the time they were
ast assessed if necessary. Proportions of patients reaching an
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
CABG  coronary artery
bypass grafting
CI  confidence interval
CVA  cerebrovascular
accident
ECG  electrocardiograph
HR  hazard ratio
MACCE  major adverse
cardiac and
cerebrovascular events
PCI  percutaneous
coronary intervention
P-PCI  primary
percutaneous coronary
intervention
re-AMI  recurrent acute
myocardial infarction
R-PCI  rescue
percutaneous coronary
intervention
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarctionnd point were compared using either the chi-square or
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The REACT Trial: Longer-Term Follow-Up July 7, 2009:118–26isher exact test as appropriate. Survival and event-free
urvival (time to first event) were plotted as Kaplan-Meier
urves, and the log-rank test was used to compare them. For
airwise comparisons, hazard ratios (HRs) with 95% con-
dence intervals (CIs) were calculated. Cox proportional
azards survival models investigated any potential influence
f the covariates (age; sex; first thrombolytic treatment;
nfarction site; previous history of AMI, angina, percutane-
us transluminal coronary angioplasty, and coronary artery
ypass grafting [CABG]; diabetes; smoking history; hyper-
ension) on treatment effects. These baseline covariates were
elected for a final model by a forward-selection procedure.
edian follow-up time has been calculated using the
eversed Kaplan-Meier method. All statistical analyses were
erformed using SAS software version 9.1 (SAS Institute,
ary, North Carolina).
esults
s previously published (12), event-free survival at 6
onths was significantly improved in patients randomized
o R-PCI, even when adjusted for age and infarct site
R-PCI vs. repeat thrombolysis or conservative therapy: p
.001 and p  0.004, respectively). All-cause mortality
howed a nonsignificant trend in favor of R-PCI (repeat
aseline Characteristics
Table 1 Baseline Characteristics
Variables, n (%)
Repeat Thrombolysis
(n  142)
Age (yrs)
Mean  SD 61.3 10.3
Range 40–85
Male sex 114 (80.3)
Medical history
Angina 32 (22.5)
Acute myocardial infarction 23 (16.2)
Percutaneous coronary intervention 6 (4.2)
Coronary artery bypass grafting 7 (4.9)
Diabetes 23 (16.2)
Hypertension 60 (42.3)
Smoking history
Currently smoking 70 (49.6)*
Formerly smoked 41 (29.1)*
Never smoked 30 (21.3)*
Anterior infarct 54 (38.0)
First thrombolytic therapy
Reteplase 43 (30.3)
Streptokinase 82 (57.7)
Tenecteplase 2 (1.4)
Tissue plasminogen activator 15 (10.6)
Time to first thrombolytic therapy (min)
Median 135
Interquartile range 94–217
Data were missing for 1 patient.hrombolysis: 12.7%; conservative therapy: 12.8%; R-PCI: a.2% [p  0.12]) and significantly fewer revascularizations
ccurred (overall p  0.05).
-year MACCE. Complete clinical follow-up at 1 year was
vailable for 388 of the 427 randomized patients (91%). The
emaining patients were censored at the time of last follow-
p. Information on all components of the primary end point
etween 6 months and 1 year were collected, and the overall
vent-free survival curve according to randomized treatment
as plotted (Fig. 1). Between 6 and 12 months, there were
further deaths in each of the repeat thrombolysis and
-PCI groups and 3 in the conservative group. There were
o further CVAs in any group, but severe heart failure
equiring admission was recorded in 3 patients randomized
o repeat thrombolysis, 2 allocated to conservative therapy,
nd 1 from the R-PCI group. The rate of event-free survival
t 1 year in patients randomized to R-PCI was 81.5%,
ompared with 64.1% in the repeat thrombolysis and 67.5%
n the conservative group (overall p  0.004). Adjusting for
ge and infarct site, the HRs at 1 year were 0.44 (95% CI:
.28 to 0.71; p  0.0008) for R-PCI versus repeat throm-
olysis and 0.51 (95% CI: 0.32 to 0.83; p  0.007) for
-PCI versus conservative therapy. There was no difference
etween the repeat thrombolysis and conservative groups
HR: 0.87; 95% CI: 0.58 to 1.30; p  0.48).
Results remain unchanged when the data are analyzed
Treatment Group
All Patients
(n  427)
Conservative Therapy
(n  141)
Rescue PCI
(n  144)
61.0 10.7 61.1 11.9 61.1 11.0
37–85 34–85 34–85
111 (78.7) 113 (78.5) 338 (79.2)
29 (20.6) 32 (22.2) 93 (21.8)
17 (12.1) 14 (9.8)* 54 (12.7)*
4 (2.8) 6 (4.2) 16 (3.7)
4 (2.8) 7 (4.9) 18 (4.2)
16 (11.3) 21 (14.6) 60 (14.1)
53 (37.6) 47 (32.6) 160 (37.5)
65 (46.1) 68 (47.2) 203 (47.7)*
42 (29.8) 40 (27.8) 123 (28.9)*
34 (24.1) 36 (25.0) 100 (23.5)*
66 (46.8) 61 (42.7)* 181 (42.5)*
28 (19.9) 42 (29.2) 113 (26.5)
88 (62.4) 84 (58.3) 254 (59.5)
5 (3.5) 3 (2.1) 10 (2.3)
20 (14.2) 15 (10.4) 50 (11.7)
150 140 140
100–210 95–240 95–220ccording to actual treatment received. Event-free survival
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July 7, 2009:118–26 The REACT Trial: Longer-Term Follow-Upt 1 year in those patients who actually received R-PCI was
3.4%, compared with 67.3% of patients randomized to
onservative therapy and 64.1% of patients who received
epeat thrombolysis (p  0.002).
-year revascularization (PCI/CABG). With no man-
ated angiography in the REACT trial (except for the
escue procedure), all revascularization was clinically driven.
lthough the differences between groups in revasculariza-
ion rates had been nonsignificant at 6 months, they reached
ignificance at 12 months (Fig. 2). Repeat revascularization
Figure 1 Event-Free Survival
Event-free survival curve to 1 year (death, myocardial infarction, cerebrovascu-
lar accident, New York Heart Association functional class III or IV heart failure).
CI  confidence interval; R-PCI  rescue percutaneous coronary intervention.
Figure 2 1-Year Revascularization HRs
Adjusted hazard ratios (HRs) and 95% CIs of revascularization at 12 months: comPCI/CABG) was required in 41 patients cumulatively
rom the repeat thrombolysis group, 40 of those randomized
o the conservative group, and 25 randomized to the R-PCI
rm. Adjusted for first thrombolytic treatment and previous
CI, the HR was 0.53 (95% CI: 0.32 to 0.86; p 0.011) for
-PCI versus repeat thrombolysis and 0.50 (95% CI: 0.30
o 0.83; p  0.007) for R-PCI versus conservative therapy.
here was no significant difference between repeat throm-
olysis and conservative therapy (HR: 1.05; 95% CI: 0.68 to
.62; p  0.84).
Analysis by actual treatment received did not change the
verall conclusion, with rate of freedom from revasculariza-
ion (PCI/CABG) being 84.9% for R-PCI, compared with
6.8% for repeat thrombolysis and 66.6% for conservative
herapy (overall p  0.001).
onger-term mortality. Live status, at median 4.4 years
rom randomization to data acquisition, was obtained for all
ut 11 patients who could not be traced due to National
ealth Service number retrieval difficulties. Of these, 3
atients had been randomized to repeat thrombolysis, 7 to
onservative therapy, and 1 to R-PCI, and data were
ensored at time of last follow-up.
Of 77 total deaths, 11.2% (n  16) (cardiovascular [CV],
efined as cardiac or cerebrovascular death: n  13) were
eported in 143 patients randomized to R-PCI, compared
ith 22.3% (n  31) (CV: n  28) of 139 patients in the
epeat thrombolysis group and 22.4% (n  30) (CV: n 
3) of 134 patients in the conservative group (overall
 0.026) (Fig. 3). Adjusted for age, previous history of
ngina, and diabetes, the HR for long-term mortality was
.41 (95% CI: 0.22 to 0.75; p  0.004) for R-PCI versus
e group versus reference group. Abbreviations as in Figure 1.parativ
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The REACT Trial: Longer-Term Follow-Up July 7, 2009:118–26epeat thrombolysis and 0.43 (95% CI: 0.23 to 0.79;
 0.006) for R-PCI versus conservative therapy. There
as no mortality difference between repeated thrombolysis
nd conservative therapy (HR: 1.04; 95% CI: 0.63 to 1.72;
 0.89) (Fig. 4).
Figure 3 Longer-Term Mortality
Abbreviations as in Figure 1.
Figure 4 Adjusted HRs for Longer-Term Mortality
Adjusted hazard ratios (HRs) and 95% CIs for longer-term mortality: comparative gFor CV deaths, the survival rates were as follows: 78.2%
or repeat thrombolysis (95% CI: 69.7% to 84.6%), 81.7%
or conservative therapy (95% CI: 73.0% to 87.8%), and
0.4% for R-PCI (95% CI: 83.9% to 94.3%) (log-rank
 0.0335). HR was 0.43 (95% CI: 0.22 to 0.83;
rsus reference group. Abbreviations as in Figure 1.roup ve
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July 7, 2009:118–26 The REACT Trial: Longer-Term Follow-Up 0.0116) for R-PCI versus repeat thrombolysis, 0.52
95% CI: 0.27 to 1.04; p  0.06280) for R-PCI versus
onservative therapy, and 0.82 (95% CI: 0.47 to 1.42;
 0.4746) for conservative therapy versus repeat throm-
olysis. When cardiac death alone was considered (n  26
or repeat thrombolysis, n  20 for conservative therapy,
nd n 13 for R-PCI), survival rates were as follows: 79.5%
or repeat thrombolysis (95% CI: 71.0% to 85.7%), 85.1%
or conservative therapy (95% CI: 77.7% to 90.1%), and
0.4% for R-PCI (95% CI: 83.9% to 94.3%) (log-rank
 0.0669). The HR was 0.46 for R-PCI versus repeat
hrombolysis (95% CI: 0.24 to 0.90; p  0.0229), 0.60 for
-PCI versus conservative therapy (95% CI: 0.30 to 1.21;
 0.1556), and 0.77 for conservative therapy versus repeat
hrombolysis (95% CI: 0.43 to 1.37; p  0.3692).
Again, the longer-term overall mortality differences re-
ain unchanged when the data are analyzed according to
ctual treatment received. The survival rate in patients who
ctually received R-PCI was 81.2%, compared with 75.6%
or repeat thrombolysis and 73.1% for conservative therapy
p  0.018). Adjusted for age, previous history of angina,
nd diabetes, the HR was 0.39 (95% CI: 0.20 to 0.74;
 0.004) for R-PCI versus repeat thrombolysis and 0.43
or R-PCI versus conservative therapy (95% CI: 0.22 to
.82; p  0.010).
ime to death. Time to death was analyzed for patients
ccording to randomized group. Although patients in the
-PCI group tended to survive longer (R-PCI: 142.5 days
range 0 to 2,215 days]; repeat lysis: 14 days [range 0 to
,470 days]; conservative therapy: 33.5 days [range 0 to
,854 days]), this was not statistically significant (p 0.10).
ensitivity analysis. As longer-term status was unavailable
or 11 patients, a sensitivity analysis favoring non–R-PCI
as performed, assuming death 1 day after the last known
ive date for the R-PCI patients and live status for the
emaining patients. Conclusions were unchanged, with
verall survival 80.0% for R-PCI versus 76.2% for repeat
hrombolysis and 72.5% for conservative therapy (overall
 0.04).
iscussion
lthough thrombolysis continues to be commonly used as
eperfusion therapy, the potential for “thrombolytic failure”
ill remain an important clinical issue. For trial purposes,
failed thrombolysis” has been previously been defined
ngiographically as failure to achieve TIMI flow grade 3
13). However, in the real world, this definition is imprac-
ical, and by consensus, thrombolytic failure is defined as
ailure to resolve the maximal ST-segment deviation by
ither 50% or 70% when the ECG is repeated at either
0 or 90 min (14,15). For the REACT trial, we chose
50% ST-segment resolution at 90 min, as 60-min ECG
ay be premature for assessing reperfusion (especially in
atients who are administered streptokinase, with its longer
eperfusion times) and 50% was regarded as pragmatically basier and more consistently determined across multiple
ites in the coronary care setting. Analgesic administration
nd patient pain threshold tend to confound the value of
ngoing pain as an indicator of lytic failure.
The publication of the REACT results led to recommen-
ation for R-PCI use being upgraded to Level of Evidence:
B (16). Historically, the studies had been small and
nderpowered and demonstrated no clear benefit of R-PCI
17–20), but this changed with the RESCUE I and II trials
n the 1990s (21), with reductions in composite rates of
eath and severe heart failure, although no benefit was seen
hen each trial was considered separately. In 2005, the
ore substantial MERLIN trial (12) demonstrated signif-
cant benefit in event-free survival driven solely by a reduc-
ion in need for revascularization, again with no differences
n the hard end points of death, re-AMI, or heart failure.
he positive early result of REACT (10) was driven by hard
linical end points that comprised components of MACCE
ather than survival alone, although the study had not been
owered for mortality as a single outcome. Revasculariza-
ion, the end point that drove the MERLIN trial, was not
art of the REACT primary composite. Despite the real-
zed expectation that outcome differences for the REACT
rial would be seen early, 1-year outcome was prospectively
et as a secondary study end point. With a trend toward
educed mortality at 6 months, additional longer-term
nalysis was also considered to be necessary. Furthermore,
eta-analyses demonstrating improved outcomes for
-PCI are based only on short-term analyses (22–24), with
ong-term analysis remaining undetermined but of interest.
At 1 year, mortality was significantly less in the R-PCI
roup compared with that of repeat thrombolysis or con-
ervative treatments. Even more compelling were the long-
erm mortality data showing for the first time a significant
ortality benefit for R-PCI out to a median of 4.4 years,
ith the median time to death extended in the R-PCI
roup. Although longer-term mortality benefit has been
emonstrated in the primary angioplasty setting, it has not
reviously been shown in the setting of rescue angioplasty.
The apparent contradictory results when compared with
he MERLIN data (25) do require consideration. Differ-
nces in mortality were seen between the 2 studies as early
s 30 days (9.8% for the MERLIN trial vs. 4.9% for the
EACT trial) and extend to the longer term for re-AMI,
evere heart failure, and stroke rates, as well as death (Table
) (26). R-PCI management differs in the 2 trials, particu-
arly with respect to stent and glycoprotein IIb/IIIa inhibitor
se, timing of trial-qualifying ECG, and rates of fibrin-
pecific thrombolytic therapy. Higher stenting rates may be
specially important. Although in a meta-analysis stenting
as not associated with a significant mortality reduction
ompared with balloon angioplasty in primary PCI, there
as a significant relationship between patients’ risk profile,
ortality benefits, and coronary stenting at 30 days (p 
.022) and 1 year (p 0.034) (27). Stenting compared with
alloon angioplasty confers greater myocardial salvage as
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The REACT Trial: Longer-Term Follow-Up July 7, 2009:118–26easured by single-photon emission computed tomography
28), which might be expected to translate to longer-term
ortality benefit. Furthermore, paired scintigraphic studies
erformed 7 to 10 days apart at 1 year demonstrated the
roportion of initial perfusion defect salvaged by rescue
ntervention to be significantly greater in the stent group
han in the angioplasty group (p  0.005) (29). Although
he tendency toward lower mortality was not significant in
his small study, nevertheless the authors concluded that
enefit from rescue mechanical reperfusion in terms of
yocardial salvage is augmented by coronary stenting, a
iew supported elsewhere (30). This explains in part the
utcome differences between the MERLIN and REACT
rials.
Published data would also support the use of glycoprotein
Ib/IIIa inhibitor use in PCI for STEMI (31), another
actor differentiating these studies, particularly as they were
ndertaken before pre-loading with 600 mg of clopidogrel
as considered standard practice. Certainly the adjunctive
lopidogrel use (32) associated with the higher stenting rate
n the REACT trial in the R-PCI arm may also have
onferred longer-term clinical benefits. Suggestions that
ortality in the REACT trial is artificially low are un-
ounded, as it is broadly in keeping with the British
ardiovascular Intervention Society in-patient figure of
.8%. However, the low 1-year stroke rate in the REACT
rial compared with the apparent high level in the MER-
IN trial may be explained by our selected low stroke-risk
opulation, and the higher rate of antiplatelet therapy
dministered to this group as a result of high stenting rates
omparison of the REACT and MERLIN Trials
Table 2 Comparison of the REACT and MERLIN Trials
RE
Conservative
Baseline characteristics
Male (%) 78.7
Mean age (yrs) 61.0
Diabetes (%) 11.3
Hypertension (%) 37.6
Current smoker (%) 46.1
Acute myocardial infarction (%) 12.1
Anterior MI (%) 46.8
First lytic streptokinase (n) 62.4
Procedural characteristics
Median pain to first lysis (min) 150
Median pain to angioplasty (min) —
Coronary stents (%) —
GP IIb/IIIa (%) —
1-year outcomes (%)
Death 14.9
Re-acute myocardial infarction 9.9
Severe heart failure* 18.4
CVA 2.8
Disparate definitions for severe heart failure noted.
CVA  cerebrovascular accident; GP  glycoprotein; MERLIN  Middlesbrough Early Revascular
reatment or Repeat Thrombolysis; R-PCI  rescue percutaneous coronary intervention.ay have influenced lower embolic stroke risk (33). It is nifficult to make comparisons between heart failure rates,
iven that the definitions were so different between the 2
rials.
Apart from the rescue procedure, there was no mandated
evascularization in the REACT trial. It is therefore of note
hat there was a significant difference at 1 year between need
or revascularization in the R-PCI arm and the non-PCI
roups. Post-STEMI angiography was not routine at the
ime of this study and remains so in the United Kingdom.
e must assume that in those treated conservatively or with
epeat thrombolysis, the residual untreated stenosis resulted
n longer-term symptoms, highlighting the DANAMI-1
DANish trial in Acute Myocardial Infarction) findings
34). Such revascularization need also supports the potential
alue of post-STEMI angiography in successful as well as
ailed thrombolysis (35).
The REACT trial has been criticized for including a
ighly selected population. The REACT trial was indeed
ifferent from other studies evaluating R-PCI in that it also
tudied repeat thrombolysis, necessitating for safety selec-
ion of patients with lower bleeding risk. However, this
lone does not explain the mortality benefit, with no
uggestion that the majority of MERLIN deaths were due
o bleeding events. It has also been suggested that low center
ecruitment rates in comparison with the MERLIN trial
ay point to some element of selection bias and account for
he differences in outcome, whereas the MERLIN trial was
single-center study, with all of the advantages and disad-
antages (including potential difficulty extrapolating to a
road variety of sites) that this entails. It is important to
MERLIN (26)
R-PCI Conservative R-PCI
78.5 74 71
61.1 62.7 63.0
14.6 14.9 11.8
32.6 30.5 40.5
47.2 37.0 41.8
9.8 13.0 11.1
42.7 40.3 48.4
58.3 96.8 96.1
140 170 180
414 — 327
68.5 — 50.3
43.4 — 3.3
7.6 12.9 14.3
3.5 14.2 10.5
11.1 31.1 26.1
2.1 1.3 5.2
to Limit Infarction; MI myocardial infarction; REACT  Rescue Angioplasty Versus ConservativeACTote that centers were gradually rolled in to the REACT
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July 7, 2009:118–26 The REACT Trial: Longer-Term Follow-Uprial, some recruiting for merely a few months, and although
lmost 75% of all patients were included from the top 10
enters (50% in the top 5), there was no correlation between
eath and total numbers recruited, indicating that low
enter recruitment had no effect on mortality.
Benefit was demonstrated in the REACT trial despite a
rolonged pain-to-balloon time. The proportion of patients
n the REACT trial with pre–R-PCI TIMI flow grade 0 to
(47%; TIMI flow grade 0 36%) versus TIMI flow grade
to 3 (53%; TIMI flow grade 3  23%) (unpublished data,
.H. Gershlick, March 20, 2009) is in keeping with that of
ther studies (36,37). It has been suggested that even
uboptimal anterograde TIMI flow (in the REACT trial,
IMI flow grade 1/2  43%) may enable some tissue
reservation and mean that even late angioplasty is benefi-
ial. Although P-PCI works due to early perfusion and late
oronary artery patency, resulting in saved muscle and
rrhythmia risk reduction, it may be that thrombolysis,
espite having failed to restore full patency, has nevertheless
llowed enough flow to attenuate myocardial cell death and
nable additional (PCI) treatment to save further myocar-
ial tissue (38) and gain at least partial benefit. Despite
ecent data suggesting an association between time delay to
-PCI and mortality (39), we are unable to confirm this
ith the REACT trial data, because subgroup analysis is
onfounded by small numbers per group.
onclusions
he results of this long-term study clearly indicate that
-PCI is the treatment option of choice in patients with
CG criteria of failed thrombolysis, reducing mortality and
omposite clinical outcomes. Although recommendations
or its use previously have relied on its effect on outcomes
uch as repeat revascularization and re-AMI, the longer-
erm REACT data demonstrate a significant effect on
ortality reduction. R-PCI should therefore be a mandated
art of any STEMI management protocols, and the current
lass IIb American Heart Association/American College of
ardiology recommendations for R-PCI in the absence of
hock, hemodynamic or electrical instability, or ongoing
schemia (40) should be revisited in future guidelines.
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